2023 World Conference on Lung Cancer (Posters)-EP12.01. Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer

EP12.01. Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This report presents the final analysis of the real-world effectiveness of sequential afatinib and osimertinib in patients with advanced-stage EGFR non-small-cell lung cancer (NSCLC), as well as a comparison with other second-line regimens. The study analyzed the time-on-treatment (TOT) and overall survival (OS) in patients who received afatinib followed by osimertinib, and compared the outcomes with a comparator group who received pemetrexed-based treatments.<br /><br />The analysis included a total of 401 patients who received first-line afatinib, with 166 having the T790M mutation and receiving second-line osimertinib, and 235 having unproven T790M mutation and receiving other second-line agents. The median TOTs on afatinib and osimertinib were 15.0 months and 11.9 months, respectively. The median OS in the osimertinib group was 54.3 months, longer than that in the comparator group.<br /><br />In patients who received osimertinib, the OS was longest in those with the Del19 mutation, with a median of 59.1 months. The study also analyzed the impact of various factors on survival outcomes using a multivariable Cox proportional hazard model.<br /><br />The report concludes that sequential afatinib and osimertinib have shown encouraging activity in Asian patients with EGFR NSCLC who acquired the T790M mutation, particularly those with the Del19 mutation. This study, one of the largest real-world studies conducted on this topic, provides important insights into the effectiveness of this treatment approach in a real-world setting.

Asset Subtitle

Tae Won Jang

Meta Tag

Speaker Tae Won Jang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

real-world effectiveness

sequential afatinib

osimertinib

advanced-stage EGFR non-small-cell lung cancer

second-line regimens

time-on-treatment

overall survival

T790M mutation

pemetrexed-based treatments

Del19 mutation